What is Integrated Diagnostics Holdings Days Payable?
Integrated Diagnostics HoldingsLSE:IDHC +0.80%58 Days Payable is 40.61 as of Mar. 2026, which is 10% below its 10-year median of 45.10. GuruFocus rates LSE:IDHC with a GF Score™ of 58/100 and a GF Value™ of $0.57 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Integrated Diagnostics Holdings ranks better than 68.95% on this metric.
The historical rank and industry rank for Integrated Diagnostics Holdings's Days Payable or its related term are showing as below:
LSE:IDHC'
s Days Payable Range Over the Past 10 Years
Min: 35.03 Med: 45.1 Max: 124.58
Current: 124.58
During the past 13 years, Integrated Diagnostics Holdings's highest Days Payable was 124.58. The lowest was 35.03. And the median was 45.10.
LSE:IDHC's Days Payable is ranked better than 68.95% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.275
vs LSE:IDHC: 124.58
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Diagnostics Holdings Days Payable Chart
LSE:IDHC vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Integrated Diagnostics Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Diagnostics Holdings Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integrated Diagnostics Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where Integrated Diagnostics Holdings's Days Payable falls into.
Integrated Diagnostics Holdings Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Diagnostics Holdings (LSE:IDHC) has a Days Payable of 40.61 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Integrated Diagnostics Holdings and its competitors. This is 10% below median its historical median of 45.10. Over the past decade, Integrated Diagnostics Holdings' Days Payable has ranged from 35.03 to 124.58. According to the industry distribution chart, Integrated Diagnostics Holdings ranks #59 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 31.1%.
Is Integrated Diagnostics Holdings' Days Payable too high?
Integrated Diagnostics Holdings' current Days Payable of 40.61 is 10% below median its 10-year median of 45.10. Over the past 10 years, this metric has ranged from a low of 35.03 to a high of 124.58. The Medical Diagnostics & Research industry median Days Payable is 67.28. Integrated Diagnostics Holdings' value of 40.61 is 39.6% below this industry median. Based on the distribution chart, Integrated Diagnostics Holdings ranks #59 out of 190 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Integrated Diagnostics Holdings has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integrated Diagnostics Holdings' Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integrated Diagnostics Holdings ranks #59 out of 190 companies for Days Payable. This puts Integrated Diagnostics Holdings in the upper half of its industry. The industry median Days Payable is 67.28. Integrated Diagnostics Holdings' value of 40.61 is 39.6% below this benchmark. Historically, Integrated Diagnostics Holdings' own Days Payable has ranged from 35.03 to 124.58 over the past decade. While the company's 10-year median is 45.10 vs. the industry median of 67.28, Integrated Diagnostics Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.28, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integrated Diagnostics Holdings's current Days Payable of 40.61 is 39.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Integrated Diagnostics Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrated Diagnostics Holdings's current Days Payable is 40.61, which is 10% below median its own 10-year median of 45.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings (LSE:IDHC) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.57, compared to a current price of $0.51 — trading 11.2% below its estimated fair value. The current Days Payable is 40.61, which is 10% below median its 10-year median of 45.10 and 39.6% below the Medical Diagnostics & Research industry median of 67.28. Integrated Diagnostics Holdings' overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Integrated Diagnostics Holdings (LSE:IDHC), the current Days Payable is 40.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrated Diagnostics Holdings (LSE:IDHC) Overvalued in 2026?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings stock appears to be undervalued.
The current stock price of $0.51 is trading 11.2% below its estimated GF Value™ of $0.57.
GuruFocus considers Integrated Diagnostics Holdings to be Modestly Undervalued.
Key valuation signals for LSE:IDHC:
Days Payable: 40.61 (10% below median its 10-year median of 45.10)
GF Value™: $0.57 vs. price of $0.51 (11.2% below fair value)
Industry Position: 39.6% below the Medical Diagnostics & Research median (#59 of 190)
No single metric tells the full story. See the LSE:IDHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrated Diagnostics Holdings Business Description
Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider, operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan, Echo-Lab in Nigeria, and Biolab KSA in Saudi Arabia. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segments: the Contract Segment, which generates key revenue, and the Walk-in Segment. It derives a majority of its revenue from services offered in Egypt.
58GF Score
Get the complete analysis for LSE:IDHC
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:IDHC has been successfully added to your 
